Anabolic steroid-induced hypogonadism: Diagnosis and treatment

Cyrus D. Rahnema, Larry I. Lipshultz, Lindsey E. Crosnoe, Jason R. Kovac, Edward Kim

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Objective To develop an understanding of hypogonadal men with a history of anabolic-androgenic steroid (AAS) use and to outline recommendations for management. Design Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria. Setting Not applicable. Patient(s) Men seeking treatment for symptomatic hypogonadism who have used nonprescribed AAS. Intervention(s) History and physical examination followed by medical intervention if necessary. Main Outcome Measures(s) Serum testosterone and gonadotropin levels, symptoms, and fertility restoration. Result(s) Symptomatic hypogonadism is a potential consequence of AAS use and may depend on dose, duration, and type of AAS used. Complete endocrine and metabolic assessment should be conducted. Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators. Conclusion(s) Although complications of AAS use are variable and patient specific, they can be successfully managed. Treatment of ASIH depends on the type and duration of AAS use. Specific details regarding a patient's AAS cycle are important in medical management.

Original languageEnglish (US)
Pages (from-to)1271-1279
Number of pages9
JournalFertility and Sterility
Volume101
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Testosterone Congeners
Hypogonadism
Therapeutics
Testosterone
Selective Estrogen Receptor Modulators
Expert Testimony
Gonadotropins
Physical Examination
Fertility
Meta-Analysis
History
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Anabolic steroid-induced hypogonadism : Diagnosis and treatment. / Rahnema, Cyrus D.; Lipshultz, Larry I.; Crosnoe, Lindsey E.; Kovac, Jason R.; Kim, Edward.

In: Fertility and Sterility, Vol. 101, No. 5, 01.01.2014, p. 1271-1279.

Research output: Contribution to journalArticle

Rahnema, CD, Lipshultz, LI, Crosnoe, LE, Kovac, JR & Kim, E 2014, 'Anabolic steroid-induced hypogonadism: Diagnosis and treatment', Fertility and Sterility, vol. 101, no. 5, pp. 1271-1279. https://doi.org/10.1016/j.fertnstert.2014.02.002
Rahnema, Cyrus D. ; Lipshultz, Larry I. ; Crosnoe, Lindsey E. ; Kovac, Jason R. ; Kim, Edward. / Anabolic steroid-induced hypogonadism : Diagnosis and treatment. In: Fertility and Sterility. 2014 ; Vol. 101, No. 5. pp. 1271-1279.
@article{60b4615434fa48349572194946a6c5e0,
title = "Anabolic steroid-induced hypogonadism: Diagnosis and treatment",
abstract = "Objective To develop an understanding of hypogonadal men with a history of anabolic-androgenic steroid (AAS) use and to outline recommendations for management. Design Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria. Setting Not applicable. Patient(s) Men seeking treatment for symptomatic hypogonadism who have used nonprescribed AAS. Intervention(s) History and physical examination followed by medical intervention if necessary. Main Outcome Measures(s) Serum testosterone and gonadotropin levels, symptoms, and fertility restoration. Result(s) Symptomatic hypogonadism is a potential consequence of AAS use and may depend on dose, duration, and type of AAS used. Complete endocrine and metabolic assessment should be conducted. Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators. Conclusion(s) Although complications of AAS use are variable and patient specific, they can be successfully managed. Treatment of ASIH depends on the type and duration of AAS use. Specific details regarding a patient's AAS cycle are important in medical management.",
author = "Rahnema, {Cyrus D.} and Lipshultz, {Larry I.} and Crosnoe, {Lindsey E.} and Kovac, {Jason R.} and Edward Kim",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.fertnstert.2014.02.002",
language = "English (US)",
volume = "101",
pages = "1271--1279",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Anabolic steroid-induced hypogonadism

T2 - Diagnosis and treatment

AU - Rahnema, Cyrus D.

AU - Lipshultz, Larry I.

AU - Crosnoe, Lindsey E.

AU - Kovac, Jason R.

AU - Kim, Edward

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective To develop an understanding of hypogonadal men with a history of anabolic-androgenic steroid (AAS) use and to outline recommendations for management. Design Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria. Setting Not applicable. Patient(s) Men seeking treatment for symptomatic hypogonadism who have used nonprescribed AAS. Intervention(s) History and physical examination followed by medical intervention if necessary. Main Outcome Measures(s) Serum testosterone and gonadotropin levels, symptoms, and fertility restoration. Result(s) Symptomatic hypogonadism is a potential consequence of AAS use and may depend on dose, duration, and type of AAS used. Complete endocrine and metabolic assessment should be conducted. Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators. Conclusion(s) Although complications of AAS use are variable and patient specific, they can be successfully managed. Treatment of ASIH depends on the type and duration of AAS use. Specific details regarding a patient's AAS cycle are important in medical management.

AB - Objective To develop an understanding of hypogonadal men with a history of anabolic-androgenic steroid (AAS) use and to outline recommendations for management. Design Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria. Setting Not applicable. Patient(s) Men seeking treatment for symptomatic hypogonadism who have used nonprescribed AAS. Intervention(s) History and physical examination followed by medical intervention if necessary. Main Outcome Measures(s) Serum testosterone and gonadotropin levels, symptoms, and fertility restoration. Result(s) Symptomatic hypogonadism is a potential consequence of AAS use and may depend on dose, duration, and type of AAS used. Complete endocrine and metabolic assessment should be conducted. Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators. Conclusion(s) Although complications of AAS use are variable and patient specific, they can be successfully managed. Treatment of ASIH depends on the type and duration of AAS use. Specific details regarding a patient's AAS cycle are important in medical management.

UR - http://www.scopus.com/inward/record.url?scp=84899953349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899953349&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2014.02.002

DO - 10.1016/j.fertnstert.2014.02.002

M3 - Article

C2 - 24636400

AN - SCOPUS:84899953349

VL - 101

SP - 1271

EP - 1279

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -